Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
  Top » Catalog » Books » Medicine » Medical General » Advances in Medicine and Biology, Volume 1 Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Central Asia: Perspectives and Present Challenges
Shopping Cart more
0 items
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Extra Cellular Matrix Protein, Lysyl Oxidase, as a Therapeutic Target for Ocular Angiogenesis pp. 367-378
Tell A Friend
Tell someone you know about this product.
Extra Cellular Matrix Protein, Lysyl Oxidase, as a Therapeutic Target for Ocular Angiogenesis pp. 367-378 $100.00
Authors:  (K.N. Sulochana, K. Coral, Biochemistry Research Department, Vision Research Foundation, Sankara Nethralaya, Chennai, India)
Abnormal angiogenesis is responsible for many human diseases and inhibiting angiogenesis is an important area of drug development. Angiogenesis, the development of new blood vessels from pre-existing vessels, is a multi-step process regulated by a variety of pro and antiangiogeneic molecules, which are potential targets for the development of drugs. Lysyl oxidase (LOX), a copper-containing amine oxidase known for its function in the maintenance of extracellular matrix integrity by catalyzing collagen and elastin cross linkages. Very recently, diverse roles have been attributed to Lysyl oxidase and these novel activities cover a spectrum of diverse biological functions such as developmental regulation, tumor suppression, cell migration, adhesion, apoptosis and cellular senescence. LOX expression has been shown to be regulated by hypoxia inducible factor-1, transforming growth factor β, tumor necrosis factor α, platelet derived growth factor, fibroblast growth factor and retinoic acid. The association of LOX in ocular pathology is currently being explored. Lowered levels of vitreous LOX has been reported in PDR and RRD. Increased choroidal neovascularization following laser induction in mice lacking Lysyl oxidase-like-1(LOXL-1) is also observed. Besides, mutations in a single gene LOXL-1 is responsible for exfoliation syndrome and exfoliative glaucoma. With the increasing flow of information in this area, it can be said that LOX is a central molecule for most of the angiogenesis related pathways and therapeutic agents influencing LOX activity will be a near future prospect for ocular angiogenesis related diseases. 

Available Options:
This Item Is Currently Unavailable.
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2020

Extra Cellular Matrix Protein, Lysyl Oxidase, as a Therapeutic Target for Ocular Angiogenesis pp. 367-378